Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers

Phase 4TerminatedNCT01108263

Georgetown University5 enrolled

Overview

* After determining if subjects meet the criteria to be included in the study they will be randomly placed in either Group 1 or 2 and patient will be blinded from randomization group. * Subjects will walk across a pressure plate to determine different areas of high pressure under the foot. This will be done before the INTEGRA application and at every other follow-up visit. * Both groups will be debrided and have pictures taken in the OR * Group 1 will have Integra Flowable Wound Matrix applied onto the wound in the OR and Group 2 will have the Integra Flowable Wound Matrix applied onto the wound and injected subcutaneously in the OR. * Subjects will be placed in a total contact cast at each visit. If wound healing occurs prior to 12 weeks, a final assessment visit will be done and the status of the healed ulcer will be assessed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Foot Ulcer

Interventions

INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject is 18 years of age or older 2. Subjects with a plantar diabetic foot wound, with or without a previous history of partial foot amputation. 3. Subject has Diabetes Mellitus (type 1 or type 2). 4. University of Texas Classification 1A with a wound area measurement ranging between 0.3-4.0cm². 5. Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study. Exclusion Criteria: 1. Subjects \< 18 years of age 2. Subject is non-diabetic 3. Subjects who present with wounds of etiology other than diabetes 4. Subject demonstrates increased signs of clinical infection 5. Has active malignant disease of any kind. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry. 6. University of Texas Classification greater than grade 1A 7. Diabetic plantar foot wounds measuring \>4.0cm² 8. Subjects who present with significant vascular or metabolic comorbidity that would preclude wound healing 9. Subjects participating in any other trials in regards to the diabetic foot ulcer

Outcomes

Primary Outcomes

Overall Decrease in Wound Size

Time frame: 12 weeks

Secondary Outcomes

Decreased Peak Plantar Pressures in Both the Static and Dynamic Phases of Gait as Compared to Pre-operative Pressure Values.